COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

Competition and Cooperation - Report on the eighth plenary meeting of ISO/TC249

Page view

On June 8, 2017, the eighth plenary meeting of the International Organization for Standardization of Traditional Chinese Medicine Technical Committee (ISO/TC249) was closed in Hong Kong, with nearly 300 participants.

 

In view of the outstanding contribution of Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “Zixin Pharmaceutical”) in the international standard of ginseng and the development of international standards for Chinese medicine, in 2017, Zixin Pharmaceutical became the eighth time of ISO/TC249. The only authorized support unit in the meeting.

 

In this honor, Li Daning, honorary director of the Chinese Medicine Association for the Testing and Certification of Chinese Herbal Medicine, told reporters that in the international standards for ginseng and the development of international standards for Chinese medicine, Zixin Pharmaceutical has done a lot of basic work, which not only strongly promotes ISO/ The development of TC249 also showed the world the attitude of Chinese enterprises to actively participate in the formulation of international standards.

 

Corporate attitude

China is the earliest country to discover and use ginseng. For example, it has been more than 4,000 years since the Shennong tasted the grass. At present, ginseng has become a must-have for the Chinese nation's gem and the homologous and health care of medicine and food.

 

As we all know, the development of China's ginseng industry is not proportional to the output. From 1980 to 2010, due to the downturn in the Chinese ginseng industry, Korean ginseng has occupied the global market and has existed as a sovereign state.

 

In the face of this situation, at the end of 2009, Jilin Province intensively introduced relevant policies for the revitalization of ginseng industry. The government made every effort to promote the Jilin ginseng industry to become bigger and stronger, to limit the annual increase of new forest land area as a cut, and set off a “Ginseng Defence War”. 

 

In 2010, Zixin Pharmaceutical entered the ginseng industry and effectively planned the Chinese ginseng industry, and participated in the formulation of corresponding policy measures and industry standards.

 

The development of a standard is crucial to the development of the industry. When South Korea proposed the standard of red ginseng, Zixin Pharmaceutical realized that it could no longer "silence" and actively invested in the standardization of ginseng. To win a stronger international discourse power for China and to help the development of the national industry, it has become the persistence and belief of Zixin Pharmaceutical's standardization work.

 

"The formulation of the ginseng national standard is a systematic project. It needs to be scientifically researched, then analyzed and formulated, and finally recognized and promoted by relevant international parties, and can reflect the value in business." Honorary Director of the Chinese Medicine Association of Chinese Medicine Testing and Certification Technology Committee Li Daning told reporters.

 

“All this is done by Zixin Pharmaceutical, not for self-interest, nor for suppressing competitors.” Guo Chunsheng, the chief consultant of Zixin Pharmaceutical, said that Zixin Pharmaceutical’s original intention was to use its own technology and resources. Advantages, contributing to the revitalization of the Chinese ginseng industry.

 

The efforts of Zixin Pharmaceutical have promoted the vigorous development of China's ginseng industry, and the data can best explain the problem.

 

After Zixin Pharmaceutical entered the ginseng industry, after a few years of market operation, the price of Chinese ginseng increased from the original four or five yuan to one hundred kilograms. The total output value of Chinese ginseng was The original 300 million yuan has grown to the current 70 billion yuan. It is estimated that by 2020, the total output value of Chinese ginseng will reach 100 billion yuan.

Mutual cooperation

 

“Chinese people participate in Korean ginseng, there is no difference in ingredients, and the quality is almost equal.” Professor Qian Zhongzhi, the chief scientist of the National Pharmacopoeia Commission, repeatedly emphasized this to reporters.

 

"Chinese medicine is China's. This is a voice that does not need to be argued. It is also speaking with strength." Lu Aiping, head of the Chinese Medicine Institute of Hong Kong Baptist University, believes that more international companies can participate in the formulation of international standards for Chinese medicine, from certain To a certain extent, it will also promote the development of the globalization of Chinese medicine.

 

From the development path of ISO/TC249, the road to international cooperation is clearly confirmed. ISO/TC249 currently has 34 members. It holds a plenary meeting from late May to early June, and the 10th plenary meeting in 2019 has accepted the invitation from Thailand.

 

The establishment of ISO/TC249 aims to promote the healthy development of traditional medicine represented by Chinese medicine in the world through standardized channels. It is in the common interest of all member states to create a pattern of mutual assistance and cooperation and common development.

 

As David Graham, chairman of the ISO/TC249 committee, said, ISO standards not only ensure quality and safety, but also increase production and stimulate industrial innovation, and promote international trade.

 

that's the truth.

 

The development of China's ginseng industry has not only threatened the ginseng industry in South Korea and other countries, but has brought practical benefits to their ginseng industry, which has increased their ginseng production and market share, thus promoting the development of global ginseng industry. 

 

In this regard, Guo Chunsheng, the chief consultant of Zixin Pharmaceutical, believes that with the increase of international enterprises engaged in ginseng trade, Chinese enterprises want to occupy a dominant position in the industry and occupy the opportunities of the industry, they need to participate more in standard setting and master the discourse. right.

 

Catching up

How to make Chinese ginseng go to the international market, increase the value of ginseng production, enhance the influence and competitiveness of Chinese ginseng culture in the world, and promote the sustainable, stable and healthy development of ginseng industry, and become the key to the branding of Chinese ginseng.

 

According to Hans Rausch, general manager of PHYTOCHEM in Germany, China's ginseng industry is rich in resources. If we can formulate international standards in time, learn from the management experience and advanced equipment and technology of Korean ginseng industry, we can not only surpass the Korean ginseng industry, but also hope to give birth to the world in the future. Leading ginseng business.

 

At present, the competition between the Chinese ginseng industry and the Korean ginseng industry has been effectively stratified. The Korean ginseng industry maintains the original traditional mysterious development model. The Chinese ginseng industry has achieved great results in high-tech research and development and international standards development. Good development.

 

Seize the opportunity and win the future. Zixin Pharmaceutical is in an important strategic opportunity period that can make a difference. At the strategic level, Zixin Pharmaceutical will focus on the development direction of “innovation + capital”, focusing on the “three-in-one” strategy of the proprietary Chinese medicine industry chain, the ginseng industry chain, the gene + technology industry chain, and the realization of “scientific and technological innovation”. The large-scale healthy ecological pattern of core competitiveness promotes the sustained, stable and healthy development of the Chinese ginseng industry and the Chinese medicine industry.

 

"The ginseng industry needs us to cherish, maintain and nurture together. Never let inferior ginseng with unqualified content or 3 or 4 years of insufficient entry into the market." Guo Chunsheng, chief consultant of Zixin Pharmaceutical, appealed that this behavior will not only It will harm the interests of consumers, reduce the trust of consumers, and cause damage to existing good market participation. The government should strengthen supervision and guidance, safeguard the good development momentum of China's ginseng industry, and provide reliable guarantee for the construction of the 100 billion ginseng industry in 2020. On June 8, 2017, the eighth plenary meeting of the International Organization for Standardization of Traditional Chinese Medicine Technical Committee (ISO/TC249) was closed in Hong Kong, with nearly 300 participants.

 

In view of the outstanding contribution of Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “Zixin Pharmaceutical”) in the international standard of ginseng and the development of international standards for Chinese medicine, in 2017, Zixin Pharmaceutical became the eighth time of ISO/TC249. The only authorized support unit in the meeting.

 

In this honor, Li Daning, honorary director of the Chinese Medicine Association for the Testing and Certification of Chinese Herbal Medicine, told reporters that in the international standard of ginseng and the development of international standards for Chinese medicine, Zixin Pharmaceutical has done a lot of basic work, which not only strongly promotes ISO/ The development of TC249 also showed the world the attitude of Chinese enterprises to actively participate in the formulation of international standards.